Health Research Alliance
Browse
De Giorgi et al MTMCD 2021.pdf (9.22 MB)

Targeting the Apoa1 locus for liver-directed gene therapy

Download (9.22 MB)
journal contribution
posted on 2023-02-07, 18:10 authored by Marco De Giorgi, Ang Li, Ayrea Hurley, Mercedes Barzi, Alexandria Doerfler, Nikitha Cherayil, Harrison Smith, Jonathan Brown, Charles Lin, Karl-Dimiter Bissig, Gang Bao, William R. Lagor

Clinical application of somatic genome editing requires therapeutics

that are generalizable to a broad range of patients. Targeted

insertion of promoterless transgenes can ensure that edits

are permanent and broadly applicable while minimizing risks of

off-target integration. In the liver, the Albumin (Alb) locus is

currently the only well-characterized site for promoterless transgene

insertion. Here, we target the Apoa1 locus with adeno-associated

viral (AAV) delivery of CRISPR-Cas9 and achieve rates of

6% to 16% of targeted hepatocytes, with no evidence of toxicity.

We further show that the endogenous Apoa1 promoter can drive

robust and sustained expression of therapeutic proteins, such as

apolipoprotein E (APOE), dramatically reducing plasma lipids

in a model of hypercholesterolemia. Finally, we demonstrate

that Apoa1-targeted fumarylacetoacetate hydrolase (FAH) can

correct and rescue the severe metabolic liver disease hereditary

tyrosinemia type I. In summary, we identify and validate

Apoa1 as a novel integration site that supports durable transgene

expression in the liver for gene therapy applications.

History

Grant ID

19POST34430092

Usage metrics

    American Heart Association

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC